Patents by Inventor Anton Neschadim

Anton Neschadim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
    Patent number: 10780179
    Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 22, 2020
    Assignee: IMMUNOBIOCHEM CORPORATION
    Inventor: Anton Neschadim
  • CONJUGATES FOR THE TREATMENT OF CANCER TARGETED AT INTRACELLULAR TUMOR-ASSOCIATED ANTIGENS
    Publication number: 20180078654
    Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 22, 2018
    Inventor: Anton Neschadim